

Synthesis of 9Z-9-Substituted Retinoic Acids by Palladium Catalyzed Coupling Reaction of a Vinyl Triflate with Alkenyl Stannanes

Akimori WADA,* Yuki NOMOTO, Kenji TANO, Eriko YAMASHITA, and Masayoshi ITO

Kobe Pharmaceutical University, 4-19-1, Motoyamakita-machi, Higashinada, Kobe 658-8558, Japan.

Received May 12, 2000; accepted June 29, 2000

Palladium catalyzed cross coupling reactions of a vinyl triflate intermediate and various alkenyl stannanes afforded trisubstituted Z-olefins stereoselectively in high yields. These olefins were then converted to the corresponding 9Z-retinoic acids via Horner–Emmons reaction and subsequent basic hydrolysis in excellent yields.

Key words retinoid X receptor; 9Z-retinoic acid analog; coupling reaction; vinyl triflate; alkenyl stannane

It is well known that all-*E*-retinoic acid **1** and 9Z-retinoic acid **2** are the ligands of retinoic acid receptors (RAR α , β , γ) and retinoid X receptors (RXR α , β , γ), respectively.¹⁾ These receptors are members of the nuclear receptor superfamily and exhibit significant biological functions including cell differentiation, cell proliferation, embryonic development, *etc.* through gene transcription.²⁾ Currently, much effort is being directed at the preparation of receptor-selective retinoids in order to define the functions of each receptor and to develop therapeutic agents.³⁾ In connection with our study on the stereoselective synthesis of retinoids and carotenoids,⁴⁾ we wish to describe here a novel synthesis of 9-substituted 9Z-retinoic acids using a palladium catalyzed cross-coupling reaction.⁵⁾

Treatment of 2,6,6-trimethyl-1-cyclohexene-1-acetaldehyde **3**,⁶⁾ prepared by Wittig reaction of β -cyclocitral with (methoxymethyl)triphenylphosphonium chloride followed by hydrolysis, with *N*-phenyltrifluoromethanesulfonimide (Tf₂NPh) in the presence of potassium *tert*-butoxide gave the vinyl triflate **4** in 58% yield as the only stereoisomer. In a preliminary study, palladium catalyzed coupling of **4** with alkenyl stannane **6a**⁷⁾ under various conditions indicated that the best results were obtained using 5 mol% tetrakis(triphenylphosphine)palladium(0) (Pd(PPh₃)₄) as catalyst at room temperature in dimethylformamide (DMF) for 2 h, to produce alcohol **9a** in 87% yield. The structure of **9a** was determined after oxidation to the aldehyde **10a** and comparison of spec-

tral data with those in the literature.⁸⁾ However, under similar conditions the reaction of **4** with alkenyl stannanes **7** or **8** having an electron withdrawing group did not proceed and the expected coupling product was not obtained.

In order to determine the generality of this coupling, we examined the reaction of **4** with various alkenyl stannanes (**6b–d**), prepared from substituted propargyl alcohols **5** according to the previously reported method,⁷⁾ and the results are listed in Table 1.

In the case of **6e**, the yield was decreased dramatically (run 5), however, the yield was improved using tris(dibenzylideneacetone)dipalladium(0) (Pd₂dba₃) with triphenylarsine (AsPh₃) as ligand⁹⁾ at room temperature with the prolonged reaction time (overnight). Oxidation of alcohols **9** with tetra-*n*-propyl ammonium per-ruthenate (TPAP)/*N*-methyl morpholine *N*-oxide (NMO)¹⁰⁾ afforded the trienals **10** in good yields. The Horner–Emmons reaction of **10** with C5-phosphonate was carried out using *n*-BuLi as a base to






Chart 1



Reagents: a) *t*-BuOK, Tf₂NPh / THF, 0°C; b) Pd(PPh₃)₄, **6a** / DMF, r.t.; c) LiAlH₄ then Bu₃SnOMe / THF, 0°C; d) MnO₂ / CH₂Cl₂, r.t.; e) (EtO)₂P(O)CH₂C(Me)=CHCO₂Et, *n*-BuLi / THF, 0°C

Chart 2



Reagents: a) Pd(PPh₃)₄, **6** / DMF, r.t.; b) TPAP, NMO / CH₂Cl₂, r.t.; c) (EtO)₂P(O)CH₂C(Me)=CHCO₂Et, *n*-BuLi / THF, 0°C; d) prep. HPLC; e) 10% KOH-EtOH, 50°C

Chart 3

* To whom correspondence should be addressed. e-mail: a-wada@kobepharm-u.ac.jp

Table 1. Yields in the Synthesis of 9-Substituted 9Z-Retinoic Acids

Run	Substituent R	Yield of 9 (%) ^{a)}	Yield of 10 (%)	Yield of 11 (%; 13E/13Z)	Yield of 12 (%)
1	Me	87	72	— ^{b)}	— ^{b)}
2	Et	88	87	80/16	95
3	Pr	87	75	53/23	Quant.
4	Bu	83	71	70/21	Quant.
5	Ph ^{c)}	43 (Quant.) ^{d)}	71	52/12	91

a) 10 mol% of Pd(PPh₃)₄ in DMF at r.t. for 2 h. b) Ref. 8. c) The stereochemistry at 9 position is *E*. d) Pd₂dba₃, AsPh₃ in DMF at r.t. for 14 h.

give esters **11** as a mixture of double bond isomers [13E:13Z=*ca.* 3:2—5:1]. After separation of the 9Z,13E-isomers by preparative high-performance liquid chromatography (HPLC), these compounds were transformed to the corresponding acids **12** by basic hydrolysis in excellent yields.

In summary, we have developed a novel method for the stereoselective synthesis of trisubstituted *Z*-olefin using the palladium catalyzed coupling reaction of a vinyl triflate with alkenyl stannanes and have achieved the synthesis of 9-substituted 9Z-retinoic acids **12**.¹¹⁾ Biological investigations with these compounds are ongoing.

Experimental

Melting points were determined on a Yanagimoto micro melting point apparatus and are uncorrected. UV spectra were recorded on a JASCO Ubest-55 instrument and IR spectra on a Perkin-Elmer FT-IR Paragon 1000 spectrometer. ¹H-NMR spectra were obtained on a Varian Gemini-200 or Gemini-300 NMR spectrometer. Mass spectra were determined on a Hitachi M-4100 instrument. Column chromatography (CC) under aspirator pressure (*ca.* 30 mmHg) was performed using Merck Silica gel 60. Preparative HPLC was conducted on a Shimadzu LC-6A instrument with a Shimadzu UV-VIS detector, SPD-6AV, using a LiChrosorb Si-60 column (5 μm), 1.0×30 cm. All reactions were carried out under a nitrogen atmosphere. THF and ether were purified by distillation from benzophenone–sodium ketyl under nitrogen. Materials obtained from commercial suppliers were used without further purification except when otherwise noted. Diisopropylamine was purified by distillation from CaH₂. Standard workup means that the organic layers were finally washed with brine, dried over anhydrous sodium sulfate (Na₂SO₄), filtered, and concentrated *in vacuo* below 30 °C using a rotary evaporator.

(E)-2-(2,6,6-Trimethylcyclohexen-1-yl)-ethenyl (trifluoromethyl)sulfonate (4) A solution of the aldehyde (**3**, 1.01 g, 6.1 mmol)⁹⁾ in THF (12 ml) was added to a stirred solution of *tert*-BuOK (2 g, 9.0 mmol) in THF (10 ml) at 0 °C. The mixture was stirred for 15 min at 0 °C, and *N*-phenyl trifluoromethanesulfonimide (2.6 g, 4.2 mmol) was added at the same temperature. After stirring for an additional 30 min at room temperature, the reaction was quenched with saturated aqueous NH₄Cl (30 ml) and extracted with Et₂O (50 ml×3), followed by standard work up. The residue was purified by CC (ether:hexane=1:4 as eluent) to give the enol triflate (**4**, 1.03 g, 58%) as a colorless oil. UV λ_{max} (EtOH) nm: 235; IR (CHCl₃) cm⁻¹: 2934, 2868, 1645, 1423, 1215, 1110; ¹H-NMR (300 MHz) δ: 0.98 (6H, s), 1.43—1.66 (4H, m), 1.69 (3H, s), 2.02 (2H, brt, *J*=6 Hz), 6.22 (1H, d, *J*=12 Hz), 6.41 (1H, d, *J*=12 Hz); HR-MS *m/z*: 298.1944 (Calcd for C₂₀H₂₆O₂: 298.1944).

General Procedure for the Preparation of 3-Substituted-3-tributylstannyl-prop-2-en-1-ols (6a—e) NaOMe (0.16 g, 0.19 mmol) was added to a solution of LiAlH₄ (1.0 mol THF solution, 43.5 ml, 43.5 mmol) at 0 °C. The mixture was cooled to 0 °C and 3-substituted prop-2-en-1-ol (20 mmol) in THF (5 ml) was slowly added. The resulting mixture was stirred 1 h at 0 °C, then EtOAc (7.3 ml) was added and the mixture stirred for 15 min at room temperature. The reaction mixture was then cooled to 0 °C, Bu₃SnOMe (11.5 ml, 39.8 mmol) was added and the resulting mixture was left at room temperature. After 2 d, MeOH (30 ml) was added and the mixture was stirred for 1 h at room temperature and poured into H₂O (700 ml). The mixture was carefully made acidic by addition of dilute HCl and the product was extracted with Et₂O (80 ml×3), followed by standard work up. The residue was purified by CC (ether:hexane=1:4 as eluent) to give stannyl alcohol (**6**) as a colorless oil.

(2Z)-3-Tributylstannyl-2-buten-1-ol (**6a**): Prepared from 2-buten-1-ol (**5a**,

1.68 g, 24 mmol) in 79% yield (6.58 g) as a colorless oil. The spectral data of this compound were identical with those in the literature.⁷⁾

(2Z)-3-Tributylstannyl-2-penten-1-ol (**6b**): Prepared from 2-pentyn-1-ol (**5b**, 1.63 g, 19 mmol) in 62% yield (4.49 g) as a colorless oil. IR (CHCl₃) cm⁻¹: 3607, 3453, 2958, 2927, 1463, 1377; ¹H-NMR (300 MHz) δ: 0.88—1.59 (30H, m), 1.15 (1H, t, *J*=6 Hz), 2.24 (2H, q, *J*=7.5 Hz), 4.05 (2H, m), 6.25 (1H, t, *J*=6.5 Hz, ³*J*_{Sn-H,trans}=127 Hz). HR-MS *m/z*: 376.1767 (Calcd for C₁₇H₃₆OSn: 376.1786).

(2Z)-3-Tributylstannyl-2-hexen-1-ol (**6c**): Prepared from 2-hexyn-1-ol (**5c**, 1.91 g, 20 mmol) in 78% yield (5.92 g) as a colorless oil. IR (CHCl₃) cm⁻¹: 3608, 3448, 2958, 2927, 1463, 1377; ¹H-NMR (300 MHz) δ: 0.87—1.59 (32H, m), 1.14 (1H, t, *J*=5.5 Hz), 2.19 (2H, t, *J*=7.5 Hz), 4.05 (2H, m), 6.23 (1H, t, *J*=6.5 Hz, ³*J*_{Sn-H,trans}=126 Hz); HR-MS *m/z*: 390.1917 (Calcd for C₁₈H₃₈OSn: 390.1942).

(2Z)-3-Tributylstannyl-2-hepten-1-ol (**6d**): Prepared from 2-heptyn-1-ol (**5d**, 2.25 g, 20 mmol) in 74% yield (5.99 g) as a colorless oil. IR (CHCl₃) cm⁻¹: 3608, 3451, 2958, 2928, 1464, 1378; ¹H-NMR (300 MHz) δ: 0.88—1.59 (34H, m), 1.15 (1H, t, *J*=6.5 Hz), 2.20 (2H, t, *J*=7 Hz), 4.05 (2H, m), 6.22 (1H, t, *J*=6.5 Hz, ³*J*_{Sn-H,trans}=129 Hz); HR-MS *m/z*: 404.2074 (Calcd for C₁₉H₄₀OSn: 404.2099).

(2Z)-3-Tributylstannyl-3-phenyl-2-buten-1-ol (**6e**): Prepared from 3-phenyl-2-buten-1-ol (**5e**, 1.42 g, 11 mmol) in 80% yield (3.65 g) as a colorless oil. The spectral data were identical with those in the literature.⁷⁾

General Procedure for the Preparation of 9Z-Aldehyde (9a—e) To a stirred solution of triflate (**4**, 200 mg, 0.67 mmol) in DMF (2 ml) was added Pd(PPh₃)₄ (40 mg, 0.034 mmol, 0.05 eq) at room temperature under nitrogen. After 10 min, a solution of tributylstannyl olefin (**5**, 300—400 mg, *ca.* 1 mmol, 1.5 eq) in DMF (2 ml) was added and the resulting mixture was stirred for 20 min. The reaction was quenched with saturated aqueous NaCl (5 ml) and extracted with Et₂O (10 ml×3), followed by the standard work up. The residue was purified by CC (ether:hexane=1:4 to 3:7 as an eluent) to give the coupled alcohol (**9**). The alcohol (**9**, 0.5 mmol) was dissolved in CH₂Cl₂ (5 ml) containing 4 Å sieves and NMO (0.1 ml, 0.75 mmol). After stirring the mixture for 10 min, TPAP (0.025 mmol) was added and the reaction followed by TLC until complete. When complete, the mixture was diluted with CH₂Cl₂ (20 ml) and washed with sodium sulphite solution (10 ml), brine (10 ml) and finally saturated copper(II) sulphate solution (10 ml). The organic layer was dried over Na₂SO₄ and concentrated. The residue was purified by CC (ether:hexane=1:4 as eluent) to give the aldehyde (**9**) as a pale yellow oil.

(2Z)-3-Methyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienal (**9a**): Prepared from triflate (**4**, 170 mg, 0.57 mmol) and stannyl olefin (**6a**, 320 mg, 0.9 mmol) in 63% yield (79 mg, 2 steps) as a colorless oil. The spectral data were identical with those in the literature.⁸⁾

(2Z)-3-Ethyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienal (**9b**): Prepared from triflate (**4**, 98 mg, 0.33 mmol) and stannyl olefin (**6b**, 188 mg, 0.5 mmol) in 76% yield (59 mg, 2 steps) as a colorless oil. UV λ_{max} (EtOH) nm: 326sh, 282; IR (CHCl₃) cm⁻¹: 2933, 1655, 1607; ¹H-NMR (300 MHz) δ: 1.05 (6H, s), 1.19 (3H, d, *J*=7.5 Hz), 1.46—1.69 (4H, m), 1.75 (3H, s), 2.06 (2H, brt, *J*=6 Hz), 2.48 (2H, q, *J*=7.5 Hz), 5.89 (1H, d, *J*=8 Hz), 6.61 (1H, d, *J*=16 Hz), 6.89 (1H, d, *J*=16 Hz), 10.15 (1H, d, *J*=8 Hz); HR-MS *m/z*: 232.1819 (Calcd for C₁₆H₂₄O: 232.1825).

(2Z)-3-Propyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienal (**9c**): Prepared from triflate (**4**, 105 mg, 0.35 mmol) and stannyl olefin (**6c**, 195 mg, 0.5 mmol) in 65% yield (56 mg, 2 steps) as a colorless oil. UV λ_{max} (EtOH) nm: 321sh, 279.5; IR (CHCl₃) cm⁻¹: 2934, 1659, 1612; ¹H-NMR (300 MHz) δ: 0.97 (3H, t, *J*=7.5 Hz), 1.04 (6H, s), 1.46—1.69 (6H, m), 1.73 (3H, s), 2.04 (2H, brt, *J*=6 Hz), 2.39 (2H, t, *J*=7 Hz), 5.86 (1H, d, *J*=8 Hz), 6.58 (1H, d, *J*=16 Hz), 6.85 (1H, d, *J*=16 Hz), 10.11 (1H, d, *J*=8 Hz); HR-MS *m/z*: 246.1987 (Calcd for C₁₇H₂₆O: 246.1983).

(2Z)-3-Butyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienal (**9d**): Prepared from triflate (**4**, 122 mg, 0.41 mmol) and stannyl olefin (**6d**, 227 mg,

0.56 mmol) in 59% yield (62 mg, 2 steps) as a colorless oil. UV λ_{\max} (EtOH) nm: 319, 267; IR (CHCl₃) cm⁻¹: 2959, 1657, 1611; ¹H-NMR (300 MHz) δ : 0.95 (3H, t, J =7.5 Hz), 1.06 (6H, s), 1.48–1.65 (8H, m), 1.75 (3H, s), 2.06 (2H, brt, J =6 Hz), 2.43 (2H, t, J =7.5 Hz), 5.89 (1H, d, J =8 Hz), 6.60 (1H, d, J =16 Hz), 6.87 (1H, d, J =16 Hz), 10.11 (1H, d, J =8 Hz); HR-MS m/z : 260.2123 (Calcd for C₁₈H₂₈O: 260.2139).

(2*E*)-3-Phenyl-5-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4-pentadienal (**9e**): Prepared from triflate (**4**, 93 mg, 0.31 mmol) and stannylenein (**6e**, 213 mg, 0.5 mmol) in 31% yield (27 mg, 2 steps) as a colorless oil.

UV λ_{\max} (EtOH) nm: 299.5; IR (CHCl₃) cm⁻¹: 2936, 1660, 1614; ¹H-NMR (300 MHz) δ : 1.04 (6H, s), 1.45–1.70 (4H, m), 1.79 (3H, s), 2.06 (2H, brt, J =6.5 Hz), 6.14 (1H, d, J =8 Hz), 6.45 (2H, d, J =16 Hz), 6.93 (1H, d, J =16 Hz), 7.43 (5H, brs), 10.14 (1H, d, J =8 Hz); HR-MS m/z : 280.1831 (Calcd for C₂₀H₂₄O: 280.1826).

General Procedure for the Preparation of Ethyl 9-Substituted Retinoate (11b–e) To a solution of diethyl 3-(methoxycarbonyl)-2-methyl-2-propenylphosphonate (*E*:*Z*=4:1) (391 mg, 2 mmol) in THF (5.5 ml) was added *n*-BuLi (1.6 M hexane solution, 1.25 ml, 2 mmol) at 0 °C. After stirring for 30 min, a solution of the aldehyde (**10**, ca. 0.7 mmol) in THF (5 ml) was added. The resulting mixture was stirred for an additional 5 h. The reaction was quenched with saturated NH₄Cl (5 ml) and extracted with ether followed by standard workup. The residue was purified by preparative HPLC (ether: benzene: hexane=1:25:74) to give the respective pentaenyl esters (**11**) as pale yellow oils.

Ethyl (2*E*/*Z*,4*E*,6*Z*,8*E*)-7-Ethyl-3-methyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoates (**11b**) These were prepared from the aldehyde (**10b**, 66 mg, 0.28 mmol) in 80% (**11b**, 56 mg) and 16% (**11b'**, 15 mg) yields, respectively.

2*E*,6*Z*-isomer **11b**: UV λ_{\max} (EtOH) nm: 349; IR (CHCl₃) cm⁻¹: 2932, 1698, 1589; ¹H-NMR (300 MHz) δ : 1.04 (6H, s), 1.15 (3H, t, J =7 Hz), 1.29 (3H, t, J =7 Hz), 1.4–1.7 (4H, m), 1.75 (3H, s), 2.05 (2H, t, J =6.5 Hz), 2.33 (3H, s), 2.34 (2H, t, J =7 Hz), 4.17 (2H, q, J =7 Hz), 5.77 (1H, s), 6.06 (1H, d, J =11.5 Hz), 6.24 (1H, d, J =15 Hz), 6.30 (1H, d, J =16.5 Hz), 6.53 (1H, d, J =16.5 Hz), 7.08 (1H, dd, J =11.5, 15 Hz); HR-MS m/z : 342.2566 (Calcd for C₂₃H₃₄O₂: 342.2557).

2*Z*,6*Z*-isomer **11b'**: UV λ_{\max} (EtOH) nm: 350.5; IR (CHCl₃) cm⁻¹: 2931, 1696, 1601; ¹H-NMR (300 MHz) δ : 1.03 (6H, s), 1.14 (3H, t, J =7 Hz), 1.30 (3H, t, J =7 Hz), 1.4–1.7 (4H, m), 1.75 (3H, s), 2.04 (2H, t, J =6.5 Hz), 2.06 (3H, s), 2.34 (2H, t, J =7 Hz), 4.16 (2H, q, J =7 Hz), 5.64 (1H, s), 6.19 (1H, d, J =12 Hz), 6.27 (1H, d, J =16 Hz), 6.53 (1H, d, J =16 Hz), 7.03 (1H, dd, J =12, 15 Hz), 7.73 (1H, d, J =15 Hz); HR-MS m/z : 342.2563 (Calcd for C₂₃H₃₄O₂: 342.2557).

Ethyl (2*E*/*Z*,4*E*,6*Z*,8*E*)-3-Methyl-9-(2,6,6-trimethylcyclohexen-1-yl)-7-propylnona-2,4,6,8-tetraenoates (**11c**): These were prepared from the aldehyde (**10c**, 160 mg, 0.65 mmol) in 53% (**11c**, 122 mg) and 22% (**11c'**, 52 mg) yields, respectively.

2*E*,6*Z*-isomer **11c**: UV λ_{\max} (EtOH) nm: 349; IR (CHCl₃) cm⁻¹: 2930, 1696, 1601; ¹H-NMR (300 MHz) δ : 0.94 (3H, t, J =7 Hz), 1.03 (6H, s), 1.28 (3H, t, J =7 Hz), 1.4–1.7 (6H, m), 1.73 (3H, s), 2.04 (2H, t, J =6.5 Hz), 2.31 (2H, t, J =7 Hz), 2.33 (3H, s), 4.16 (2H, q, J =7 Hz), 5.76 (1H, s), 6.04 (1H, d, J =11 Hz), 6.23 (1H, d, J =15 Hz), 6.28 (1H, d, J =16 Hz), 6.51 (1H, d, J =16 Hz), 7.07 (1H, dd, J =11, 15 Hz); HR-MS m/z : 356.2698 (Calcd for C₂₄H₃₆O₂: 356.2713).

2*Z*,6*Z*-isomer **11c'**: UV λ_{\max} (EtOH) nm: 351.5; IR (CHCl₃) cm⁻¹: 2932, 1698, 1601; ¹H-NMR (300 MHz) δ : 0.90 (3H, t, J =7 Hz), 1.04 (6H, s), 1.28 (3H, t, J =7 Hz), 1.4–1.7 (6H, m), 1.74 (3H, s), 2.04 (2H, t, J =6.5 Hz), 2.05 (3H, s), 2.31 (2H, t, J =7 Hz), 4.16 (2H, q, J =7 Hz), 5.63 (1H, s), 6.15 (1H, d, J =12 Hz), 6.28 (1H, d, J =15 Hz), 6.51 (1H, d, J =16 Hz), 7.07 (1H, dd, J =11, 15 Hz), 7.73 (1H, d, J =16 Hz); HR-MS m/z : 356.2712 (Calcd for C₂₄H₃₆O₂: 356.2713).

Ethyl (2*E*/*Z*,4*E*,6*Z*,8*E*)-7-Butyl-3-methyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoates (**11d**): These were prepared from the aldehyde (**10d**, 98 mg, 0.38 mmol) in 70% (**11d**, 97 mg) and 21% (**11d'**, 29 mg) yields, respectively.

2*E*,6*Z*-isomer **11d**: UV λ_{\max} (EtOH) nm: 350, 244.5; IR (CHCl₃) cm⁻¹: 2932, 1699, 1602; ¹H-NMR (300 MHz) δ : 0.94 (3H, t, J =7 Hz), 1.05 (6H, s), 1.30 (3H, t, J =7 Hz), 1.4–1.7 (8H, m), 1.65 (3H, s), 2.06 (2H, t, J =6 Hz), 2.34 (2H, t, J =7 Hz), 2.35 (3H, s), 4.18 (2H, q, J =7 Hz), 5.77 (1H, s), 6.05 (1H, d, J =11.5 Hz), 6.24 (1H, d, J =15 Hz), 6.29 (1H, d, J =16 Hz), 6.52 (1H, d, J =16 Hz), 7.07 (1H, dd, J =11.5, 15 Hz); HR-MS m/z : 370.2883 (Calcd for C₂₅H₃₈O₂: 370.2870).

2*Z*,6*Z*-isomer **11d'**: UV λ_{\max} (EtOH) nm: 350, 244.5; IR (CHCl₃) cm⁻¹: 2933, 1698, 1589; ¹H-NMR (300 MHz) δ : 0.90 (3H, t, J =7 Hz), 1.05 (6H, s), 1.29 (3H, t, J =7 Hz), 1.4–1.7 (8H, m), 1.75 (3H, s), 2.04 (2H, t,

J =6.5 Hz), 2.05 (3H, s), 2.34 (2H, t, J =7 Hz), 4.17 (2H, q, J =7 Hz), 5.64 (1H, s), 6.15 (1H, d, J =11 Hz), 6.28 (1H, d, J =16 Hz), 6.51 (1H, d, J =16 Hz), 7.07 (1H, dd, J =11, 15 Hz), 7.73 (1H, d, J =15 Hz); HR-MS m/z : 370.2884 (Calcd for C₂₅H₃₈O₂: 370.2870).

Ethyl (2*E*/*Z*,4*E*,6*E*,8*E*)-3-Methyl-9-(2,6,6-trimethylcyclohexen-1-yl)-7-phenylnona-2,4,6,8-tetraenoates (**11e**): These were prepared from the aldehyde (**10e**, 69 mg, 0.25 mmol) in 52% (**11e**, 49 mg) and 12% (**11e'**, 12 mg) yields, respectively.

2*E*,6*E*-isomer **11e**: UV λ_{\max} (EtOH) nm: 360, 286, 246; IR (CHCl₃) cm⁻¹: 2933, 1698, 1606; ¹H-NMR (300 MHz) δ : 1.02 (6H, s), 1.30 (3H, t, J =7 Hz), 1.4–1.7 (4H, m), 1.81 (3H, s), 2.05 (2H, t, J =6 Hz), 2.38 (3H, s), 4.19 (2H, q, J =7 Hz), 5.81 (1H, s), 6.18 (1H, d, J =16 Hz), 6.26 (1H, d, J =11.5 Hz), 6.37 (1H, d, J =15 Hz), 6.68 (1H, d, J =16 Hz), 7.19 (1H, dd, J =11.5, 15 Hz); HR-MS m/z : 390.2566 (Calcd for C₂₇H₃₄O₂: 390.2557).

2*Z*,6*E*-isomer **11e'**: UV λ_{\max} (EtOH) nm: 362, 291, 248; IR (CHCl₃) cm⁻¹: 2930, 1670, 1602; ¹H-NMR (300 MHz) δ : 1.00 (6H, s), 1.29 (3H, t, J =7 Hz), 1.4–1.7 (4H, m), 1.79 (3H, s), 2.05 (2H, t, J =6.5 Hz), 2.09 (3H, s), 4.17 (2H, q, J =7 Hz), 5.68 (1H, s), 6.18 (1H, d, J =16 Hz), 6.39 (1H, d, J =11 Hz), 6.65 (1H, d, J =16 Hz), 7.17 (1H, dd, J =11, 15 Hz), 7.73 (1H, d, J =15 Hz); HR-MS m/z : 390.2563 (Calcd for C₂₇H₃₄O₂: 390.2557).

General Procedure for the Preparation of 9*Z*-Retinoic Acid Analogs (12b–e) A mixture of the ester (**11**, ca. 40 mg, 0.1 mmol) and 25% NaOH solution (5 ml) in methanol (5 ml) was heated at 50 °C for 30 min. After cooling, the reaction mixture was made acidic with 5% HCl, and the organics were extracted with ethyl acetate followed by standard workup. The residue was purified by CC (ethyl acetate: hexane=3:1 as eluent) to give the acid (**12**, 23 mg, 98%) as a yellow solid.

(2*E*,4*E*,6*Z*,8*E*)-7-Ethyl-3-methyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic Acid (**12b**): Prepared from the ester (**11b**, 43 mg, 0.13 mmol) in 95% (38 mg) yield. mp. 125–127 °C (ether–*n*-hexane); UV λ_{\max} (EtOH) nm: 339; IR (CHCl₃) cm⁻¹: 3300–2600, 1681, 1586; ¹H-NMR (300 MHz) δ : 1.04 (6H, s), 1.15 (3H, t, J =7.5 Hz), 1.4–1.7 (4H, m), 1.75 (3H, s), 2.05 (2H, t, J =7 Hz), 2.35 (3H, s), 2.38 (2H, t, J =7.5 Hz), 5.79 (1H, s), 6.07 (1H, d, J =12 Hz), 6.27 (1H, d, J =16 Hz), 6.32 (1H, d, J =15 Hz), 6.53 (1H, d, J =16 Hz), 7.13 (1H, dd, J =12, 15 Hz); a COOH signal was not present; HR-MS m/z : 314.2251 (Calcd for C₂₁H₃₀O₂: 314.2244).

(2*E*,4*E*,6*Z*,8*E*)-3-Methyl-9-(2,6,6-trimethylcyclohexen-1-yl)-7-propylnona-2,4,6,8-tetraenoic Acid (**12c**): Prepared from the ester (**11c**, 58 mg, 0.16 mmol) in quantitative (53 mg) yield. mp 125–127 °C (ether–*n*-hexane); UV λ_{\max} (EtOH) nm: 340; IR (CHCl₃) cm⁻¹: 3350–2600, 1679, 1586; ¹H-NMR (300 MHz) δ : 0.94 (3H, t, J =7 Hz), 1.03 (6H, s), 1.4–1.7 (6H, m), 1.74 (3H, s), 2.04 (2H, t, J =6.5 Hz), 2.32 (2H, t, J =7 Hz), 2.34 (3H, s), 5.79 (1H, s), 6.05 (1H, d, J =11 Hz), 6.25 (1H, d, J =15 Hz), 6.29 (1H, d, J =16 Hz), 6.51 (1H, d, J =16 Hz), 7.12 (1H, dd, J =11, 15 Hz); a COOH signal was not present; HR-MS m/z : 328.2416 (Calcd for C₂₂H₃₂O₂: 328.2401).

(2*E*,4*E*,6*Z*,8*E*)-7-Butyl-3-methyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic Acid (**12d**): Prepared from the ester (**10d**, 23 mg, 0.06 mmol) in quantitative (21 mg) yield. mp 135–136 °C (ether–*n*-hexane); UV λ_{\max} (EtOH) nm: 345.5; IR (CHCl₃) cm⁻¹: 3300–2600, 1678, 1585; ¹H-NMR (300 MHz) δ : 0.94 (3H, t, J =7 Hz), 1.04 (6H, s), 1.4–1.7 (8H, m), 1.76 (3H, s), 2.06 (2H, t, J =6 Hz), 2.34 (2H, t, J =7 Hz), 2.35 (3H, s), 5.80 (1H, s), 6.06 (1H, d, J =11.5 Hz), 6.27 (1H, d, J =15 Hz), 6.31 (1H, d, J =16 Hz), 6.52 (1H, d, J =16 Hz), 7.14 (1H, dd, J =11.5, 15 Hz); a COOH signal was not present; HR-MS m/z : 342.2572 (Calcd for C₂₃H₃₄O₂: 342.2557).

(2*E*,4*E*,6*E*,8*E*)-3-Methyl-9-(2,6,6-trimethylcyclohexen-1-yl)-7-phenylnona-2,4,6,8-tetraenoic Acid (**12e**): Prepared from the ester (**11e**, 23 mg, 0.06 mmol) in 91% (20 mg) yield. mp 148–150 °C (ether–*n*-hexane); UV λ_{\max} (EtOH) nm: 339; IR (CHCl₃) cm⁻¹: 3300–2600, 1681, 1603, 1583; ¹H-NMR (300 MHz) δ : 1.00 (6H, s), 1.4–1.7 (4H, m), 1.79 (3H, s), 2.05 (2H, t, J =6 Hz), 2.37 (3H, s), 5.70 (1H, s), 6.17 (1H, d, J =16 Hz), 6.27 (1H, d, J =11 Hz), 6.37 (1H, d, J =15 Hz), 6.67 (1H, d, J =16 Hz), 7.23 (1H, dd, J =11, 15 Hz); a COOH signal was not present; HR-MS m/z : 362.2260 (Calcd for C₂₅H₃₀O₂: 362.2244).

Acknowledgment This work was supported in part by the Kobe Pharmaceutical University Collaboration Fund and The Science Research Promotion Fund from the Japan Private School Promotion Foundation.

References and Notes

- Mangelsdorf D. J., Umesono K., Evans R. M., "The Retinoids," 2nd ed., by Sporn M. B., Roberts A. B., Goodman D. S., Raven Press, New York, 1994, pp. 319–350.
- a) Heyman R. A., Mangelsdorf D. J., Dyck J. A., Stein R. B., Eichele

- G., Evans R. M., Thaller C., *Cell*, **68**, 397—406 (1992); b) Hong W. K., Sporn M. B., *Science*, **278**, 1073—1077 (1997).
- 3) a) Viligonda V., Garst M. E., Chandraratna R. A. S., *Bioorg. Med. Chem. Lett.*, **9**, 589—594 (1999); b) Wong M. F., Repa J. J., Clagett-Dame M., Curley R. W., Jr., *ibid.*, **7**, 2313—2318 (1997); c) Yu K.-L., Chen S., Ostrowski J., Trampusch K. M., Reczek P. R., Mansuri M. M., Starrett J. E., Jr., *ibid.*, **6**, 2859—2864 (1996); d) Trost B. M., Harms A. E., *Tetrahedron Lett.*, **37**, 3971—3974 (1996); e) Boehm M. F., Zhang L., Zhi L., McClurg M. R., Berger E., Wagoner M., Mais D. E., Suto C. M., Davis P. J. A., Heyman R. A., Nadzan A. M., *J. Med. Chem.*, **38**, 3146—3155 (1995); f) Boehm M. F., Zhang L., Badea B. A., White S. K., Mais D. E., Berger E., Suto C. M., Goldman M. E., Heyman R. A., *ibid.*, **37**, 2930—2941 (1994); g) Vaezi M. F., Alam M., Sani B. P., Rogers T. S., Simpson-Herren L., Wille J. J., Hill D. L., Doran T. I., Branillette W. J., Muccio D. D., *ibid.*, **37**, 4499—4507 (1994).
- 4) a) Wada A., Hiraishi S., Ito M., *Chem. Pharm. Bull.*, **42**, 757—759 (1994); b) Wada A., Tanaka Y., Fujioka N., Ito M., *Bioorg. Med. Chem. Lett.*, **6**, 2049—2052 (1996); c) Wada A., Hiraishi S., Takamura N., Date T., Aoe K., Ito M., *J. Org. Chem.*, **62**, 4343—4348 (1997); d) Wada A., Fujioka N., Tanaka Y., Ito M., *ibid.*, **65**, 2438—2443 (2000).
- 5) Several similar cross coupling reactions for the stereoselective synthesis of retinoids have already been reported; for all-*E*-retinoids, a) Torrado A., Iglesias B., López S., de Lara A. R., *Tetrahedron*, **51**, 2435—2453 (1995); b) Torrado A., López S., Alvarez R., de Lara A. R., *Synthesis*, **1995**, 285—293; c) Thibonnet J., Abarbri M., Duchêne A., Parrain J.-L., *Synlett*, **1999**, 141—143; d) Dominguez B., Iglesias B., de Lera A. R., *J. Org. Chem.*, **63**, 4135—4139 (1998); For 9*Z*-retinoic acid, e) Pazos Y., de Lera A. R., *Tetrahedron Lett.*, **40**, 8287—8290 (1999); For 11*Z*-retinal, f) Uenishi J., Kawahama R., Yonemitsu O., Wada A., Ito M., *Angew. Chem. Int. Ed. Engl.*, **37**, 320—323 (1998).
- 6) Engler T. A., Sampath U., Naganathan S., Velde D. V., Takuasgawa F., *J. Org. Chem.*, **54**, 5712—5727 (1989).
- 7) Havránek M., Dvůrák D., *Synthesis*, **1998**, 1264—1268.
- 8) Bennai Y. L., *J. Org. Chem.*, **61**, 3542—3544 (1996).
- 9) Farina V., Krishnan B., *J. Am. Chem. Soc.*, **113**, 9585—9595 (1991).
- 10) Griffith W. P., Ley S. V., Whitecombe G. P., White A. D., *J. Chem. Soc., Chem. Commun.*, **1987**, 1625—1627.
- 11) According to nomenclature, **12e** is the 9*E*-isomer.